Vaxart says its tablet delivery platform has simplified vaccine production so significantly it may bring manufacturing currently contracted to Lonza back in-house.
An influenza vaccine produced in tobacco plants could make a big impact in the market if it reaches the market in the US in time for the 2018-19 flu season, says a market analyst.
Influenza research completed just before the US banned ‘gain-of-function’ studies could help vaccine makers boost virus yields and accelerate production say scientists.
Takeda is closing three US R&D facilities and relocating its global HQ to a site in Massachusetts as part of plans to consolidate its vaccine business.
Medicago has ploughed $245m into an influenza vaccine plant that will use a tobacco-based technology it says produces high yields quicker than with egg-based platforms.
Seattle-based Infectious Disease Research Institute (IDRI) has received $4m in funding from the US Biomedical Advanced Research and Development Authority (BARDA) to develop an adjuvant manufacturing hub with both preclinical and clinical expertise to...
US government scientists told a House subcommittee on oversight and investigations on Tuesday that the six months production time necessary for flu vaccine manufacturers can create difficulties for health experts selecting the appropriate virus strains...
Flu vaccine maker Protein Sciences, and Japan-based UMN Pharma and IHI Corp. have entered into an agreement to assess the feasibility of sourcing the active ingredients of Flublok influenza vaccine from Japan.
Baxter has sold its pandemic flu portfolio and Vero cell technology to Nanotherapeutics in preparation for the launch of its haematology and oncology-based spinout company Baxalta.
Novartis’ seasonal flu vaccine Fluad has been deemed safe by the Italian Medicines Agency (AIFA) after testing the two batches connected to over a dozen deaths.
Italy has suspended the use of Fluad despite Novartis saying no causal relationship has been established between its seasonal flu vaccine and three deaths.
The World Health Organisation says a meeting between drugmakers and high-level government representatives last week has yielded plans to fast-track scale-up of Ebola vaccines in the face of incomplete trials and leaked production problems.
